

Physicians Laboratory Services Cumulative Antimicrobial Susceptibility Report
 Family Practice/Specialist Offices, All Isolates | January 2022 - December 2022

| % Susceptible Gram Positive | Total* | Penicillin(2) | Ampicillin | Oxacillin(1) | Amoxicillin/Clavulanate | Cefotaxime(2) | Ceftriaxone(2) | Meropenem | Gentamicin | Ciprofloxacin(7) | Levofloxacin(7) | Moxifloxacin | Trimethoprim/Sulfa | Clindamycin(5) | Daptomycin(6) | Erythromycin(5) | Nitrofurantoin(3) | Linezolid(4) | Vancormycin | Tetracycline(7) | Gentamicin Synergy(8) | Streptomycin Synergy(8) | Penicillin (non-CSF)(2) | Penicillin V (oral)(2) | Cefotaxime (non-CSF)(2) | Ceftriaxone (non-CSF)(2) | |
|---|--------|---------------|------------|--------------|-------------------------|---------------|----------------|-----------|------------|------------------|-----------------|--------------|--------------------|----------------|---------------|-----------------|-------------------|--------------|-------------|-----------------|-----------------------|-------------------------|-------------------------|------------------------|-------------------------|--------------------------|----|
| <i>Staph. aureus</i> (MSSA) 75% | 522 | -- | -- | 100 | -- | -- | -- | -- | 99 | 90 | 91 | 99 | 99 | 77 | 100 | 68 | 99 | 100 | 100 | 96 | -- | -- | -- | -- | -- | -- | -- |
| <i>Staph. aureus</i> (MRSA) 25% | 174 | -- | -- | 0 | -- | -- | -- | -- | 93 | 39 | 40 | 87 | 97 | 71 | 99 | 17 | 94 | 100 | 100 | 92 | -- | -- | -- | -- | -- | -- | -- |
| <i>Staph. spp.</i> (coagulase-negative) | 635 | -- | -- | 58 | -- | -- | -- | -- | 95 | 78 | 79 | 94 | 79 | 72 | 100 | 56 | 99 | 100 | 100 | 85 | -- | -- | -- | -- | -- | -- | -- |
| <i>Strep. pneumoniae</i> | 26 | 65 | -- | -- | 96 | 88 | 88 | 86 | -- | -- | 100 | -- | 69 | 88 | -- | 68 | -- | -- | 100 | 73 | -- | -- | 96 | 57 | 96 | 100 | |
| <i>Enterococcus faecalis</i> | 774 | 100 | 100 | -- | -- | R | R | -- | -- | 87 | 93 | -- | R | R | 100 | -- | 100 | 100 | 100 | 31 | -- | -- | -- | -- | -- | -- | -- |
| <i>Enterococcus faecium</i> | 44 | 36 | 36 | -- | -- | R | R | -- | -- | 27 | 34 | -- | R | R | 98 | -- | 76 | 100 | 64 | 36 | -- | -- | -- | -- | -- | -- | -- |
| <i>Enterococcus spp.</i> | 13 | 85 | 85 | -- | -- | R | R | -- | -- | 85 | 85 | -- | R | R | 100 | -- | 82 | 100 | 85 | 54 | -- | -- | -- | -- | -- | -- | -- |

The % susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

R Organism has intrinsic resistance to this antimicrobial.

-- Not tested/indicated for organism.

* Antibiograms created for organisms with less than 30 total isolates have questionable statistical significance. Interpret data with caution.

(1) Oxacillin predicts susceptibility to most cephalosporins, carbapenems, and beta-lactam/beta-lactamase inhibitors.

(2) For *S. pneumoniae*: cefotaxime, ceftriaxone, and penicillin % susceptible listed is based on parenteral CSF (meningitis), parenteral non-CSF, and oral MIC breakpoints.

(3) Nitrofurantoin is reported for isolates from urine only.

(4) Linezolid is reported for isolates from non-urine sources only.

(5) For *Staphylococcus spp.*: clindamycin and erythromycin are reported for isolates from non-urine sources only.

(6) For *Staphylococcus spp.*: daptomycin is reported for isolates from non-respiratory sources only.

(7) For all *Enterococcus spp.*: ciprofloxacin, levofloxacin, and tetracycline are reported for isolates from urine only.

(8) For *E. faecalis* and *E. faecium*: gentamicin and streptomycin high-level resistance testing is reported for isolates from blood cultures only.

Physicians Laboratory Services Cumulative Antimicrobial Susceptibility Report
Family Practice/Specialist Offices, All Isolates | January 2022 - December 2022

| % Susceptible Gram Negative | Total* | Ampicilin | Ampicilin/Sulbactam | Piperacillin/Tazobactam | Cefazolin | Ceftazidime | Ceftazidime/Avibactam | Ceftriaxone | Cefepime | Cefoxitin | Aztreonam | Ertapenem | Imipenem | Meropenem | Amikacin | Gentamicin | Tobramycin | Ciprofloxacin(3) | Levofloxacin(3) | Trimethoprim/Sulfa | Nitrofurantoin (1) | Tetracycline(2) | Tigecycline |
|--|--------|------------------------------|---------------------|-------------------------|-----------|-------------|-----------------------|-------------|----------|-----------|-----------|-----------|----------|-----------|----------|------------|------------|------------------|-----------------|--------------------|--------------------|-----------------|-------------|
| <i>Escherichia coli</i> | 5553 | 62 | 67 | 98 | 78 | 94 | 100 | 94 | 95 | 97 | 94 | 100 | 100 | 100 | 100 | 93 | 95 | 87 | 88 | 81 | 97 | 79 | 100 |
| <i>Klebsiella pneumoniae</i> | 1025 | R | 87 | 99 | 90 | 96 | 100 | 96 | 96 | 96 | 96 | 100 | 100 | 100 | 100 | 98 | 98 | 97 | 98 | 91 | 41 | 86 | 99 |
| <i>Proteus mirabilis</i> | 411 | 91 | 95 | 100 | 81 | 99 | 100 | 98 | 99 | 99 | 99 | 100 | -- | 100 | 100 | 95 | 95 | 86 | 93 | 89 | R | R | -- |
| <i>Klebsiella (Enterobacter) aerogenes</i> | 166 | R | R | 91 | R | 82 | 100 | 81 | 100 | R | 86 | 97 | 82 | 100 | 100 | 100 | 100 | 99 | 100 | 100 | 25 | 96 | 100 |
| <i>Enterobacter cloacae</i> complex | 224 | R | R | 84 | R | 74 | 100 | 63 | 98 | R | 73 | 90 | 93 | 100 | 100 | 99 | 98 | 97 | 99 | 88 | 27 | 89 | 99 |
| <i>Serratia marcescens</i> | 51 | R | R | 76 | R | 76 | 100 | 86 | 100 | R | 80 | 100 | -- | 100 | 100 | 100 | 96 | 96 | 98 | 96 | R | 8 | 100 |
| <i>Pseudomonas aeruginosa</i> | 353 | R | R | 97 | R | 97 | 99 | R | 95 | R | 92 | R | 88 | 96 | 97 | 90 | 98 | 94 | 94 | R | -- | R | -- |
| <i>Acinetobacter baumannii</i> | 5 | R | 100 | -- | R | 100 | -- | 60 | 100 | R | R | R | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | -- | 100 | -- |
| <i>Citrobacter freundii</i> complex | 183 | R | R | 94 | R | 81 | 100 | 80 | 98 | R | 81 | 100 | 99 | 100 | 99 | 96 | 96 | 95 | 97 | 85 | 94 | 83 | 99 |
| <i>Morganella morganii</i> | 35 | R | 0 | 100 | R | 83 | 100 | 83 | 100 | 66 | 89 | 97 | 0 | 100 | 100 | 77 | 91 | 80 | 91 | 71 | R | R | 0 |
| <i>Providencia</i> spp. | 27 | R | 59 | 93 | R | 70 | 85 | 96 | 100 | 96 | 74 | 96 | 76 | 100 | 100 | 78 | 78 | 81 | 85 | 93 | R | R | 0 |
| <i>Salmonella</i> spp. | 5 | 100 | -- | -- | -- | 100 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 100 | 100 | -- | -- | -- |
| <i>Shigella</i> spp. | 0 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| <i>Stenotrophomonas</i> | 11 | R | R | R | R | 45 | -- | R | -- | R | R | R | R | R | R | R | R | -- | 82 | 100 | -- | R | -- |
| <i>Klebsiella oxytoca</i> | 216 | R | 68 | 95 | 17 | 94 | 100 | 91 | 94 | 100 | 91 | 100 | 100 | 100 | 100 | 97 | 95 | 94 | 94 | 98 | 89 | 92 | 100 |
| <i>Haemophilus influenzae</i> | 45 | Beta-lactamase positive: 33% | | | | | | | | | | | | | | | | | | | | | |

The % susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.

R Organism has intrinsic resistance to this antimicrobial.

-- Not tested/indicated for organism.

* Antibigrams created for organisms with less than 30 total isolates have questionable statistical significance. Interpret data with caution.

(1) Nitrofurantoin is reported for isolates from urine only.

(2) For *A. baumannii*: tetracycline is reported for isolates from urine only.

(3) Ciprofloxacin/Levofloxacin: Enterobacterales & *P. aeruginosa* %Susceptible utilizes CLSI M100 28th Edition breakpoints.